JP2014516993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516993A5 JP2014516993A5 JP2014513790A JP2014513790A JP2014516993A5 JP 2014516993 A5 JP2014516993 A5 JP 2014516993A5 JP 2014513790 A JP2014513790 A JP 2014513790A JP 2014513790 A JP2014513790 A JP 2014513790A JP 2014516993 A5 JP2014516993 A5 JP 2014516993A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- conjugate
- fmoc
- mal
- fms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002202 Polyethylene glycol Substances 0.000 claims 30
- 229920001223 polyethylene glycol Polymers 0.000 claims 30
- 101800001388 Oxyntomodulin Proteins 0.000 claims 29
- 102400000319 Oxyntomodulin Human genes 0.000 claims 29
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 22
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 22
- 102100040918 Pro-glucagon Human genes 0.000 claims 22
- 230000009977 dual effect Effects 0.000 claims 22
- 229940123232 Glucagon receptor agonist Drugs 0.000 claims 20
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims 19
- 125000005647 linker group Chemical group 0.000 claims 17
- 239000008177 pharmaceutical agent Substances 0.000 claims 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 7
- -1 9-fluorenylmethoxycarbonyl (Fmoc) Chemical class 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- JLPNPVIABCLANH-UHFFFAOYSA-N 9-[(2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl]-7-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]-9h-fluorene-2-sulfonic acid Chemical compound C=1C(S(=O)(=O)O)=CC=C(C2=CC=C(NC(=O)CCN3C(C=CC3=O)=O)C=C22)C=1C2COC(=O)ON1C(=O)CCC1=O JLPNPVIABCLANH-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 4
- 101500028776 Homo sapiens Oxyntomodulin Proteins 0.000 claims 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 3
- 108010063919 Glucagon Receptors Proteins 0.000 claims 2
- 102100040890 Glucagon receptor Human genes 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492448P | 2011-06-02 | 2011-06-02 | |
| US61/492,448 | 2011-06-02 | ||
| US201261624589P | 2012-04-16 | 2012-04-16 | |
| US61/624,589 | 2012-04-16 | ||
| PCT/US2012/040744 WO2012167251A1 (en) | 2011-06-02 | 2012-06-04 | Long-acting glp-1/glucagon receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516993A JP2014516993A (ja) | 2014-07-17 |
| JP2014516993A5 true JP2014516993A5 (https=) | 2015-07-23 |
| JP6182134B2 JP6182134B2 (ja) | 2017-08-16 |
Family
ID=47259955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513790A Active JP6182134B2 (ja) | 2011-06-02 | 2012-06-04 | 長時間作用型ｇｌｐ−１／グルカゴン受容体アゴニスト |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140349922A1 (https=) |
| EP (1) | EP2714070B1 (https=) |
| JP (1) | JP6182134B2 (https=) |
| KR (1) | KR102092206B1 (https=) |
| CN (1) | CN104023739A (https=) |
| AU (1) | AU2012261869B2 (https=) |
| BR (1) | BR112013030933A2 (https=) |
| CA (1) | CA2837710C (https=) |
| CL (1) | CL2013003450A1 (https=) |
| CO (1) | CO6980619A2 (https=) |
| EA (1) | EA201391764A1 (https=) |
| ES (1) | ES2981891T3 (https=) |
| HK (1) | HK1201478A1 (https=) |
| IL (1) | IL229732B (https=) |
| MX (2) | MX346957B (https=) |
| SG (1) | SG10201606243YA (https=) |
| WO (1) | WO2012167251A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| BR112014025951A2 (pt) | 2012-04-19 | 2017-07-11 | Opko Biologics Ltd | variantes de oxintomodulina de longa ação e métodos de produção do mesmo |
| MX362432B (es) | 2012-06-04 | 2019-01-17 | Opko Biologics Ltd | Variantes de oxm pegilada. |
| EA033788B1 (ru) | 2012-11-20 | 2019-11-26 | Opko Biologics Ltd | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| EP3098235A4 (en) | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) * | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| HRP20230405T8 (hr) | 2014-12-10 | 2023-09-29 | Opko Biologics Ltd. | Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta |
| JP2018517697A (ja) * | 2015-05-29 | 2018-07-05 | オプコ バイオロジクス リミテッド | ペグ化オキシントモジュリン変異体 |
| ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
| AR105284A1 (es) * | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| CN108602894A (zh) * | 2015-10-30 | 2018-09-28 | 纽约州立大学研究基金会 | 胃泌酸调节素类似物及其制备和使用方法 |
| CN113456802A (zh) * | 2015-12-29 | 2021-10-01 | 派格生物医药(苏州)股份有限公司 | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 |
| EP3468610A1 (en) * | 2016-06-09 | 2019-04-17 | OPKO Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| RU2764197C1 (ru) | 2016-09-23 | 2022-01-14 | Ханми Фарм. Ко., Лтд. | Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение |
| AR111341A1 (es) | 2017-03-23 | 2019-07-03 | Hanmi Pharm Ind Co Ltd | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo |
| EP3713993B1 (en) | 2017-11-23 | 2024-07-10 | Sentigel Ab | Hydrogel composition and its uses |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| EP3924369A1 (en) | 2019-02-11 | 2021-12-22 | OPKO Biologics Ltd. | Long-acting glp-2 analogs |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| KR20250176951A (ko) | 2024-06-12 | 2025-12-22 | 주식회사 에스엔바이오사이언스 | 펩타이드 유도체와 알부민을 포함하는 약제학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| CA2521784C (en) * | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| CN101389648B (zh) * | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| EP2341942A1 (en) * | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| BRPI1013626B8 (pt) * | 2009-03-20 | 2021-05-25 | Hanmi Holdings Co Ltd | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico |
| AR079344A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
-
2012
- 2012-06-04 CN CN201280038726.3A patent/CN104023739A/zh active Pending
- 2012-06-04 HK HK15102153.2A patent/HK1201478A1/xx unknown
- 2012-06-04 CA CA2837710A patent/CA2837710C/en active Active
- 2012-06-04 MX MX2013014069A patent/MX346957B/es active IP Right Grant
- 2012-06-04 EA EA201391764A patent/EA201391764A1/ru unknown
- 2012-06-04 MX MX2015011960A patent/MX386803B/es unknown
- 2012-06-04 SG SG10201606243YA patent/SG10201606243YA/en unknown
- 2012-06-04 WO PCT/US2012/040744 patent/WO2012167251A1/en not_active Ceased
- 2012-06-04 BR BR112013030933A patent/BR112013030933A2/pt not_active IP Right Cessation
- 2012-06-04 AU AU2012261869A patent/AU2012261869B2/en active Active
- 2012-06-04 JP JP2014513790A patent/JP6182134B2/ja active Active
- 2012-06-04 US US14/123,106 patent/US20140349922A1/en active Pending
- 2012-06-04 EP EP12793107.9A patent/EP2714070B1/en active Active
- 2012-06-04 KR KR1020137035156A patent/KR102092206B1/ko active Active
- 2012-06-04 ES ES12793107T patent/ES2981891T3/es active Active
-
2013
- 2013-11-28 IL IL229732A patent/IL229732B/en unknown
- 2013-12-02 CL CL2013003450A patent/CL2013003450A1/es unknown
- 2013-12-27 CO CO13301132A patent/CO6980619A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516993A5 (https=) | ||
| US8257682B2 (en) | Compositions for delivery of therapeutics and other materials | |
| US20200392498A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| US20160257961A1 (en) | Polynucleotide constructs having disulfide groups | |
| CA2677041C (en) | Multimeric conjugate | |
| US7790140B2 (en) | Compositions for delivery of therapeutics and other materials, and methods of making and using the same | |
| EA023503B1 (ru) | Галогенводородная солевая форма конъюгата многолучевого полимера и лекарственного средства, способ ее приготовления, композиции и способ лечения рака | |
| CA2521784A1 (en) | Reversible pegylated drugs | |
| JP2017512752A5 (https=) | ||
| NZ543122A (en) | An HIV fusion inhibitor peptide covalently linked to a blood protein | |
| JP2013523896A5 (https=) | ||
| RU2010105921A (ru) | Инсулин-олигомерные конъюгаты, их препараты и применения | |
| JP2011500725A5 (https=) | ||
| WO2018060310A1 (en) | Dosage regimen for a controlled-release pth compound | |
| TWI861015B (zh) | 包含抗原肽-佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物 | |
| EP3518982A1 (en) | Incremental dose finding in controlled-release pth compounds | |
| JP2014516049A5 (https=) | ||
| WO2006089156A2 (en) | Drug-polymer conjugates coupled to a peptidic carrier | |
| JP2024523524A (ja) | リガンド薬物コンジュゲート及びその応用 | |
| ES2386575T3 (es) | Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación | |
| JP2012526847A5 (https=) | ||
| JP2024512761A (ja) | タンパク質－高分子コンジュゲートおよびその使用方法 | |
| US9827338B2 (en) | GRP-R agonistic 177-lutetium-labeled bombesin derivatives for diagnosis and treatment of prostate cancer | |
| AU2021386899B2 (en) | Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto | |
| KR100888371B1 (ko) | 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제 |